Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dissolution test acceptance sampling plans

Y Tsong1, T Hammerstrom, K Lin

  • 1Division of Biometrics, U.S. Food and Drug Administration, Rockville, Maryland 20857, USA.

Journal of Biopharmaceutical Statistics
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inclusive Search for Anomalous Single-Photon Production in MicroBooNE.

Physical review letters·2026
Same author

First Search for Dark Sector e^{+}e^{-} Explanations of the MiniBooNE Anomaly at MicroBooNE.

Physical review letters·2026
Same author

Determinants and long-term outcomes of treatment delays in young and middle-aged acute ischemic stroke patients: a prospective cohort study.

BMC neurology·2026
Same author

First Measurement of Charged-Current Muon-Neutrino-Induced K^{+} Production on Argon Using the MicroBooNE Detector.

Physical review letters·2026
Same author

Search for an Anomalous Production of Charged-Current ν_{e} Interactions without Visible Pions across Multiple Kinematic Observables in MicroBooNE.

Physical review letters·2025
Same author

First Measurement of ν_{e} and ν[over ¯]_{e} Charged-Current Single Charged-Pion Production Differential Cross Sections on Argon Using the MicroBooNE Detector.

Physical review letters·2025

The U.S. Pharmacopeia (USP) dissolution testing rules are crucial for quality control but may not always reject batches with poor tablet dissolution performance. Further review and modifications are needed for robust pharmaceutical quality assurance.

Area of Science:

  • Pharmaceutical Sciences
  • Drug Manufacturing
  • Quality Control

Background:

  • The U.S. Pharmacopeia (USP) provides general monographs for drug dissolution testing.
  • USP acceptance rules are integral to pharmaceutical quality control and lot release sampling.
  • Current USP rules are widely used in the industry for batch acceptance.

Purpose of the Study:

  • To review and compare the operating characteristics of standard USP acceptance rules for dissolution.
  • To evaluate a selected modification of USP acceptance rules.
  • To assess the sensitivity of USP rules to true mean dissolution and identify potential weaknesses.

Main Methods:

  • Analysis of operating characteristics curves (OCCs) for USP dissolution acceptance rules.
  • Comparison of standard USP rules against a modified sampling plan.

Related Experiment Videos

  • Evaluation of lot rejection performance based on dissolution profiles.

    • Main Results:

    • USP acceptance rules demonstrate sensitivity to the true mean dissolution of drug products.
    • The standard USP rules may fail to reject lots with a significant percentage of tablets below the dissolution specification.
    • Operating characteristics curves highlight limitations in detecting certain types of dissolution failures.

    Conclusions:

    • Standard USP dissolution acceptance rules may not be sufficiently protective against all dissolution failures.
    • Modifications to USP rules might be necessary to enhance the detection of substandard drug batches.
    • Further research into optimized sampling plans is recommended for pharmaceutical quality assurance.